News

Elis Reports Strong Revenue Growth for 2024 Financial Year

Elis Reports Strong Revenue Growth for 2024 Financial Year

Elis Achieves Remarkable Revenue Growth in 2024

Elis, a global leader in circular services, reported a record revenue of €4.57 billion in 2024, reflecting a significant increase of 6.1% compared to the previous year.

The estimated financial results for 2024 align with previously communicated targets: Adjusted EBITDA is projected at approximately 35.2%, while free cash flow is expected to exceed €340 million.

The total revenue for 2024, amounting to €4,573.7 million, was primarily driven by a robust organic growth rate of 5.2%.

Key Factors Behind Revenue Growth

Several key initiatives contributed to this remarkable performance:

  • The year witnessed the signing of numerous new contracts, stemming from commercial strategies aimed at leveraging local growth opportunities across various countries.
  • A positive price effect was observed across all operational regions, largely due to wage inflation impacting costs.
  • Elis’s customer retention rate returned to its normative level, which highlights the company’s commitment to service quality and maintaining strong commercial relationships.
  • In Germany, the organic growth rate reached around 8%, showing no significant signs of economic slowdown.
  • The hospitality sector showed mixed performance, with disappointing results in the summer season but a more promising end to the year.
  • In the last quarter, organic revenue growth stood at 5.0%, showcasing the resilience of Elis’s business model amidst a sluggish economic environment.

Strategic Acquisitions and Expansion Efforts

Continuing its strategy of targeted acquisitions, Elis made significant strides in 2024:

  • The acquisitions of Moderna and Wasned in the Netherlands allowed Elis to bolster its offerings in the local flat linen market, thereby enhancing its network density.
  • Elis also ventured into Asia by acquiring Wonway, tapping into the thriving cleanroom market in Malaysia.
  • Integration processes for these acquisitions are progressing according to planned timelines, with a contribution of approximately 1.2% to total revenue growth in 2024.
  • Since the beginning of 2025, Elis has consolidated three additional acquisitions: Carsan in Spain, Ernst in Germany, and Bodensee in Switzerland, collectively adding around €50 million to annual revenue.

Financial Metrics and Future Outlook

Elis’s financial metrics for 2024 are in accordance with the objectives set earlier:

  • The EBITDA margin for 2024 is estimated at around 35.2%, reflecting a one percentage point increase from 2023.
  • The EBIT margin is anticipated to be around 16.0%, with headline net income per share exceeding €1.75 on a fully diluted basis.
  • The financial leverage ratio decreased by 0.2x as of December 31, 2024, compared to the previous year.
  • It’s important to note that financial data regarding the financial year ending December 31, 2024, is based on estimated and unaudited figures.
  • The complete group results for 2024 will be disclosed on March 6, 2025, prior to market opening.

Xavier Martiré, Chairman of the Management Board of Elis, commented on the financial results, stating, "2024 marked a significant milestone for Elis, achieving record revenue nearly reaching €4.6 billion, aided by robust organic growth and strategic acquisitions."

He further highlighted the solid commercial dynamism observed in workwear across all geographic markets, attributing it to numerous initiatives executed throughout the year. Despite challenges posed by the Olympic and Paralympic Games affecting tourism activities, especially in Paris, the organization remained optimistic, noting the sustainable solutions implemented to cope with rising workforce costs.

Looking ahead, Martiré expressed confidence that the Group's operational capabilities and commitment to circular economic principles would sustain its leadership position and explore lucrative growth opportunities.

Frequently Asked Questions

What was the total revenue for Elis in 2024?

The total revenue reported by Elis for 2024 was €4.57 billion, reflecting a growth of 6.1% compared to 2023.

How did Elis achieve its organic revenue growth?

Elis achieved organic revenue growth of 5.2% driven by new contracts, effective pricing strategies, and improved customer retention rates.

What acquisitions did Elis undertake in 2024?

In 2024, Elis acquired Moderna and Wasned in the Netherlands, and Wonway in Malaysia, expanding its operations and market presence.

What are the future plans for Elis?

Elis plans to continue its strategy of targeted acquisitions and leverage its operational capabilities to explore new growth opportunities.

What is the projected free cash flow for 2024?

Elis expects its free cash flow to exceed €340 million for the financial year 2024.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 184

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 135

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 177

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
D-Wave Investors Must Decide by Dec 15 Class Suit

Updated Category News Views 14

Facing the Class Action Deadline There's nothing like a looming deadline to stir the pot, and that's exactly what's happening with D-Wave Quantum Inc. (NASDAQ: QBTS) as it faces the heat of a class action lawsuit. Investors who got caught in the slide between February 26, 2026, and August 25, 2026, need to sharpen their pencils and mark December 15, 2026, on their...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 12

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 84

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 176

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 98

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 280

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Software Development with Agentic AI Features

Updated Category News Views 167

Progress Software Unveils New AI Features in Telerik and Kendo UI Progress Software is leading the way in enhancing application development with its latest update to Telerik and Kendo UI. This innovative release introduces groundbreaking agentic capabilities designed to empower developers with advanced tools for building enterprise-grade applications efficiently. With...

Continue Reading
Hao Pan's Share Transactions Reveal Insights at Orion Corporation

Updated Category News Views 245

Insights into Recent Share Transactions at Orion Corporation Orion Corporation actively engages in managing its share transactions, reflecting transparency and accountability within its operations. Recently, a significant disclosure involving Hao Pan, a senior manager at Orion Corporation, was shared under the guidelines of the Market Abuse Regulation. Who is Hao Pan? Hao...

Continue Reading
Analyzing Toast's Market Performance and Investor Sentiment

Updated Category News Views 142

Understanding Toast's Market Movements Toast Inc (NYSE: TOST) has recently seen a noticeable increase in the short percent of its float, which has risen to 9.06% compared to previous reports. This increase reflects a significant amount of activity, with approximately 32.58 million shares sold short. This statistic translates to 6.62% of all shares actively available for...

Continue Reading
Anthony Scaramucci Shares Insights on Memecoins and Digital Assets

Updated Category News Views 206

Scaramucci's View on Memecoins Renowned financial expert, Anthony Scaramucci, founder of SkyBridge Capital and an advocate for cryptocurrency, has made headlines with his bold predictions regarding the future of memecoins. He believes that the trajectory of these digital assets is likely set towards a decline. Limited Utility of Memecoins Identifying the Risks During a...

Continue Reading
Strengthening China-Africa Partnerships for a Shared Future

Updated Category News Views 121

Strengthening China-Africa Partnerships for Progress Recently, Chinese President Xi Jinping hosted a banquet attended by dignitaries from Africa and around the world, celebrating the strong ties between China and Africa. This event highlighted a shared commitment to building a community with a common future, showcasing how these two regions are collaborating for mutual...

Continue Reading